Prognostic Impact of Blood Transfusion After Primary Angioplasty for Acute Myocardial Infarction Analysis From the CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) Trial
Nikolsky E, Mehran R, Sadeghi HM, Grines CL, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Fahy M, Lansky AJ, Stone GW. Prognostic Impact of Blood Transfusion After Primary Angioplasty for Acute Myocardial Infarction Analysis From the CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) Trial. JACC Cardiovascular Interventions 2009, 2: 624-632. PMID: 19628185, DOI: 10.1016/j.jcin.2009.05.004.Peer-Reviewed Original ResearchMeSH KeywordsAbciximabAge FactorsAgedAnemiaAngioplasty, Balloon, CoronaryAntibodies, MonoclonalErythrocyte TransfusionFemaleHeart DiseasesHumansImmunoglobulin Fab FragmentsKaplan-Meier EstimateMaleMiddle AgedMyocardial InfarctionOdds RatioPlatelet Aggregation InhibitorsProportional Hazards ModelsProspective StudiesRadiographyRecurrenceRisk AssessmentRisk FactorsSeverity of Illness IndexSex FactorsStrokeTime FactorsTreatment OutcomeConceptsPrimary percutaneous coronary interventionAcute myocardial infarctionPrimary PCIRBC transfusionCADILLAC trialClinical outcomesComposite major adverse cardiac eventsAcute Myocardial Infarction AnalysisMajor adverse cardiac eventsCoronary artery bypass surgeryRed blood cell transfusionMechanical reperfusion therapyAdverse cardiac eventsArtery bypass surgeryBlood cell transfusionTriple vessel diseasePercutaneous coronary interventionBaseline anemiaMajor bleedingTransfusion propensityCell transfusionIndex hospitalizationMultivariable adjustmentPrimary angioplastyReperfusion therapy